Slowing and reversing heart and skeletal muscle degeneration in Duchenne muscular dystrophy (DMD) patients with the PTP1B inhibitor MSI-1436
Novobioscience Non-confidential report
Novobioscience Toronto 2020. Lead Mike Kelly
Slowing and reversing heart and skeletal muscle degeneration in Duchenne muscular dystrophy (DMD) patients with the PTP1B inhibitor MSI-1436
Novo Bioscience requested advice from TACT on their plans to develop MSI-1436, a PTP1B inhibitor that demonstrated initial muscle regenerative activity in a number of preclinical models. The company plans to advance the program to clinical development with the objective to slow or reverse cardiac and skeletal muscle degeneration in DMD patients. In response to the applicant’s questions and as a result of comprehensive discussions, the committee were able to make recommendations that included advice for future safety and efficacy studies in additional pre-clinical animal models. The report also made suggestions on further studies to address target engagement in patients and potential clinical trial endpoints. TACT welcomed the chance to review this interesting proposal to repurpose an agent for use in DMD.
Novo Bioscience requested advice from TACT on their plans to develop MSI-1436, a PTP1B inhibitor that demonstrated initial muscle regenerative activity in a number of preclinical models. The company plans to advance the program to clinical development with the objective to slow or reverse cardiac and skeletal muscle degeneration in DMD patients. In response to the applicant’s questions and as a result of comprehensive discussions, the committee were able to make recommendations that included advice for future safety and efficacy studies in additional pre-clinical animal models. The report also made suggestions on further studies to address target engagement in patients and potential clinical trial endpoints. TACT welcomed the chance to review this interesting proposal to repurpose an agent for use in DMD.
Name of applicant: Kevin Strange Reviewed: October, 2020 in Toronto, ON, Canada
Novobioscience Toronto 2020. Lead Mike Kelly
Slowing and reversing heart and skeletal muscle degeneration in Duchenne muscular dystrophy (DMD) patients with the PTP1B inhibitor MSI-1436
Novo Bioscience requested advice from TACT on their plans to develop MSI-1436, a PTP1B inhibitor that demonstrated initial muscle regenerative activity in a number of preclinical models. The company plans to advance the program to clinical development with the objective to slow or reverse cardiac and skeletal muscle degeneration in DMD patients. In response to the applicant’s questions and as a result of comprehensive discussions, the committee were able to make recommendations that included advice for future safety and efficacy studies in additional pre-clinical animal models. The report also made suggestions on further studies to address target engagement in patients and potential clinical trial endpoints. TACT welcomed the chance to review this interesting proposal to repurpose an agent for use in DMD.
Novo Bioscience requested advice from TACT on their plans to develop MSI-1436, a PTP1B inhibitor that demonstrated initial muscle regenerative activity in a number of preclinical models. The company plans to advance the program to clinical development with the objective to slow or reverse cardiac and skeletal muscle degeneration in DMD patients. In response to the applicant’s questions and as a result of comprehensive discussions, the committee were able to make recommendations that included advice for future safety and efficacy studies in additional pre-clinical animal models. The report also made suggestions on further studies to address target engagement in patients and potential clinical trial endpoints. TACT welcomed the chance to review this interesting proposal to repurpose an agent for use in DMD.
